5.0 on Google

← Back to Research Hub

BPC-157: Published Research, Chemical Identity and Batch Documentation

BPC-157 is a synthetic 15-amino-acid peptide (C62H98N16O22, 1419.5 g/mol) studied mainly in rats and cultured cells. Published animal and cell studies have examined it in tendon, ligament and muscle injury models and in angiogenesis signaling. Vial & Error supplies BPC-157

Vial & Error identity card for BPC-157: formula C62H98N16O22, 1419.5 g/mol
BPC-157 identity card: formula C62H98N16O22, computed molecular weight 1419.5 g/mol (PubChem CID 9941957).

Batch documentation

Every Vial & Error batch is held to a 98%+ purity floor and is backed by two separate records: the manufacturer COA and a third-party test from ACS Peptide Testing Labs. The current ACS result for BPC-157 is below.

Batch testedVE2026-bpc-001
LaboratoryACS Peptide Testing Labs
Accession numberAAHV635
Purity (LCMS-UV)99.88%
Mass identificationBPC-157
ReportedJuly 28, 2026

Results apply only to the sample the lab tested. View the COA and ACS report on the BPC-157 product page.

What is BPC-157? Chemical identity

SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val [1]
CAS number137525-51-0 [PubChem]
Molecular formulaC62H98N16O22 [PubChem]
Molecular weight1419.5 g/mol (computed, free peptide) [PubChem]
PubChem CID9941957 [PubChem]

Identity values from PubChem CID 9941957. Salt forms (for example acetate) have a higher molecular weight; the batch COA governs.

What have published studies on BPC-157 examined?

Before you read the table: every row describes an animal or in-vitro experiment, and the doses and concentrations are copied as published. They are literature reference only, not guidance, recommendations or protocols for any use.

Published BPC-157 study conditions in non-human models and in-vitro systems
Model typeModelConcentration or dose (as reported)RouteDurationOutcome (as reported)Source
Animal + in vitroRat, transected Achilles tendon; cultured rat tendocytes10 µg, 10 ng or 10 pg/kg body weight, once daily (as reported)IntraperitonealAssessed days 1–14Higher load of failure, Young's modulus and Achilles functional index vs saline controls; in culture, no growth effect alone but opposed 4-hydroxynonenal growth inhibitionStaresinic M 2003 [1]
PMID 14554208 · DOI
Ex vivo / in vitroRat Achilles tendon explants and tendon fibroblastsNot stated in abstract (dose-dependent design)Culture mediumNot stated in abstractFaster explant outgrowth; no direct effect on proliferation; higher survival under H2O2 stress; dose-dependent migration; increased FAK and paxillin phosphorylationChang CH 2011 [2]
PMID 21030672 · DOI
In vitroRat Achilles tendon fibroblastsNot stated in abstract (dose- and time-dependent design)Culture mediumNot stated in abstractIncreased growth hormone receptor mRNA and protein; JAK2 activation when growth hormone was addedChang CH 2014 [3]
PMID 25415472 · DOI
Animal + in vitroChick chorioallantoic membrane; human vascular endothelial cells in culture; rat hind-limb ischemiaNot stated in abstractNot stated in abstractNot stated in abstractHigher vessel density; faster blood-flow recovery in ischemic rat muscle; increased VEGFR2 expression and VEGFR2–Akt–eNOS activationHsieh MJ 2017 [4]
PMID 27847966 · DOI
AnimalRat, transected medial collateral ligament10 µg or 10 ng/kg once daily; 1.0 µg/g cream; 0.16 µg/mL in drinking water (as reported)Intraperitoneal, topical, or oral (drinking water)Up to 90 daysFunctional, biomechanical, macroscopic and histological improvements vs controlsCerovecki T 2010 [5]
PMID 20225319 · DOI
AnimalRat, gastrocnemius muscle crush injuryNot stated in abstractIntraperitoneal or topical creamUp to 14 daysLess hematoma and edema; improved microscopic, functional and enzyme measures vs controlsNovinscak T 2008 [6]
PMID 18668315 · DOI
Animal (pharmacokinetics)Rats and beagle dogsSingle IV dose; single IM doses at three levels; repeated IM (values not stated in abstract)Intravenous, intramuscularSingle and repeated administrationElimination half-life under 30 min; linear kinetics; IM bioavailability about 14–19% (rats) and 45–51% (dogs); excreted in urine and bileHe L 2022 [7]
PMID 36588717 · DOI

Anecdotal or calculation only. Not dosing guidance or medical advice. For laboratory research use only.

Values come from PubMed abstracts only. A cell reading "Not stated in abstract" means the figure appears only in the full paper, and we left it out rather than guess.

What mechanisms have been reported for BPC-157?

Each statement below is limited to what the cited rat, dog or cell-culture study reported.

  • In cultured rat tendon fibroblasts, BPC-157 increased cell migration and the phosphorylation of FAK and paxillin without directly changing proliferation. [2]
  • In rat tendon fibroblasts, BPC-157 increased growth hormone receptor expression at the mRNA and protein level. [3]
  • In endothelial cells and a rat hind-limb ischemia model, BPC-157 was associated with increased VEGFR2 expression and activation of VEGFR2–Akt–eNOS signaling. [4]
  • In rats and beagle dogs, intact BPC-157 had an elimination half-life under 30 minutes and was metabolized into small peptide fragments and amino acids. [7]

Storage notes for BPC-157 (supplier guidance)

Supplier guidance, unconfirmed: the supplier lists −20 °C, desiccated, for long-term storage and 2–8 °C for short-term storage, away from light. Let the vial reach room temperature before opening so condensation does not form.

This page cites no stability study for BPC-157, and nothing here establishes how stable a reconstituted solution is. Use your laboratory’s validated procedures.

Why researchers source BPC-157 from Vial & Error

  • A published ACS Peptide Testing Labs report is on file.
  • Two independent records back the 98%+ purity floor: the manufacturer COA and the ACS report.
  • The study table cites primary papers, each with a PMID and DOI link.

Order BPC-157 with its COA on file

The BPC-157 product page carries the current COA section, along with ordering.

Review BPC-157 product details Send BPC-157 straight to checkout

Prefer to plan the solution first? Run the molarity numbers at 1419.5 g/mol before you order.

Frequently asked questions

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. PubChem lists its formula as C62H98N16O22 and its computed molecular weight as 1419.5 g/mol (CID 9941957).

What models has BPC-157 been studied in?

The studies in our table used rats, beagle dogs, chick chorioallantoic membrane, rat tendon explants and fibroblasts, and human vascular endothelial cell cultures. Each row is labeled as animal or in vitro.

What is the molecular weight of BPC-157 for molarity calculations?

PubChem lists 1419.5 g/mol for the free peptide. Salt forms such as acetate weigh more, so use the molecular weight on your batch COA when it differs.

Which BPC-157 batch was tested by ACS Peptide Testing Labs?

The current ACS Peptide Testing Labs report lists purity by LCMS-UV and mass identification for the sample tested. Results apply only to the sample the lab tested.

How should lyophilized BPC-157 be stored?

Supplier guidance, not yet confirmed against manufacturer stability data: desiccated at −20 °C for long-term storage and 2–8 °C for short-term storage, away from light.

Are the BPC-157 study doses guidance?

No. Concentrations and doses in the table are quoted from rat and cell experiments for literature reference. They are not guidance for any use, and BPC-157 from Vial & Error is

References

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PMID 14554208 · doi:10.1016/S0736-0266(03)00110-4
  2. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID 21030672 · doi:10.1152/japplphysiol.00945.2010
  3. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID 25415472 · doi:10.3390/molecules191119066
  4. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PMID 27847966 · doi:10.1007/s00109-016-1488-y
  5. Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. PMID 20225319 · doi:10.1002/jor.21107
  6. Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008. PMID 18668315 · doi:10.1007/s00595-007-3706-2
  7. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. PMID 36588717 · doi:10.3389/fphar.2022.1026182

[PubChem] National Center for Biotechnology Information. PubChem Compound Summary, CID 9941957.

Prepared by Vial & Error Labs LLC. Last updated November 16, 2026.

Research Use Only. Not for human or veterinary consumption.

Ask Kim
Vial & Error Labs LLC
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.